What’s In Store For CROs, CDMOs – “Stay In Your Swim Lane”, Consolidation, Divestitures
Executive Summary
Brian Scanlan, operating partner (life sciences), Edgewater Capital Partners, in an interview with Scrip, outlines where things may be headed in the CRO/CDMO segment amid big pharma streamlining efforts, “belt tightening” by emerging biopharma, down rounds and heightened geopolitical tension.